Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men.
The possible involvement of endogenous opioids in the gamma-aminobutyric acid-controlled (GABAergic) inhibition of growth hormone (GH) and prolactin (PRL) during physical exercise was evaluated in normal men. After fasting overnight, seven subjects were tested on four mornings at least 1 week apart. Exercise was performed on a bicycle ergometer. The workload was gradually increased at 3-min intervals until exhaustion and lasted about 15 min in all subjects. Tests were carried out under administration of placebo, the opioid antagonist naloxone (10 mg as an iv bolus injection), the GABAergic agonist sodium valproate (600 mg in three divided doses orally) or naloxone plus sodium valproate. During exercise, plasma GH and PRL levels rose 5.5- and 1.9-fold, respectively. The administration of naloxone did not modify, whereas sodium valproate significantly reduced the plasma GH and PRL rise during exercise. In the presence of sodium valproate, GH and PRL levels rose 3- and 1.5-fold, respectively, in response to exercise. When naloxone was given together with sodium valproate, both GH and PRL responses to exercise were abolished completely. These data suggest the involvement of a GABAergic mechanism in the regulation of GH and PRL responses to physical exercise in men. Furthermore, the data argue against a role of naloxone-sensitive endogenous opioids in the control of these hormonal responses to exercise, whereas they suggest a modulation by opioids of the GABAergic inhibitory action.
Department of Internal Medicine, School of Medicine, University of Parma, Italy.
V
V
Coiro
R
R
Volpi
M L
ML
Maffei
A
A
Caiazza
G
G
Caffarri
L
L
Capretti
R
R
Colla
P
P
Chiodera
D000328:Adult; D000704:Analysis of Variance; D015444:Exercise / Q000502:physiology*; D013006:Growth Hormone / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism*; D012016:Reference Values; D014635:Valproic Acid / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D009270:Naloxone; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D011388:Prolactin; D013006:Growth Hormone